Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Outlook Therapeutics Inc market cap is $107.14M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Outlook Therapeutics Inc 52 week high is $2.54 as of November 14, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Outlook Therapeutics Inc 52 week low is $0.1611 as of November 14, 2026.
Outlook Therapeutics Inc stock price today is $0.413.
Outlook Therapeutics Inc stock price yesterday was $0.4401.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Outlook Therapeutics Inc's P/E ratio is -0.38.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Outlook Therapeutics Inc P/B ratio is -7.4347.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Outlook Therapeutics Inc 50-day moving average is $0.5635.
